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Introduction
AJ>olipoprotein E
Apolipoprotein E (apoE) is a 34-kDa protein component of many lipoproteins
including very low-density lipoproteins (VLDL), chylomicrons, and high density
lipoproteins. ApoE plays a major role in their metabolism by mediating high-affinity
binding oflipoproteins to receptors (Mahley, 1998). Receptor-lipoprotein binding
initiates cellular uptake and degradation of the lipoproteins, making the lipid available for
intracellular metabolism. ApoE therefore, serves as a ligand for the receptor-mediated
clearance oflipoproteins from the plasma (Rall et al., 1982).
The apoE gene is located on chromosome 19 and contains 3597 nucleotides and
four exons. ApoE is encoded by an 1163 nucleotide mRNA (Mahley, 1988). In humans,
there are three common isoforms of apoE. The most common isoform is apoE3, which
contains cysteine and arginine at positions 112 and 158, respectively. Both positions
contain cysteine in apoE2 and arginine in apoE4 (Weisgraber, 1994). The allele
frequencies found in several populations are as follows: 0.07 for apoE2, 0.78 for apoE3,
and 0.14 for apoE4 (Hallman et al., 1991).
Role of apoE in the Nervous System
ApoE is the major apolipoprotein in the brain and cerebrospinal fluid (CSF) with
astrocytes being the major apoE producing cells in the brain (Pitas et al., 1987).
Microglia also produce apoE in the central nervous system (CNS) (Nathan et al., 2001).
Neurons are not known to secrete apoE (Pitas et al., 1987). Among CSF lipoproteins,
apoE is the only apolipoprotein that can interact with lipoprotein receptors. Cells within
the brain express four receptors for apoE-containing lipoproteins: low density lipoprotein
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(LDL) receptor, LDL receptor-related protein (LRP), VLDL receptor, and glycoprotein
(gp) 330. The LDL receptor and LRP receptor are expressed by neurons (Pitas et al.,

1987; Boyles et al., 1985). It has been shown that some neurons express the VLDL
receptor, and that ependymal cells express the gp330 receptor (W"tllnow et al., 1992;
Sakai et al., 1994; Kim et al.; 1996 & Kounnas et al., 1994). It has been reported that the
LDL receptor and LRP receptor mediate the binding and internalization of apoEcontaining lipoproteins in cultured neurons (Bellosta et al., 1995). These studies provide
evidence that the apoE and apoE-containing lipoproteins are present within the brain
where they can interact with neurons and that lipoprotein transport by apoE is important
for normal functioning of adult neurons.
Studies of apoE in the maintenance and repair of peripheral nervous system (PNS)
and CNS nerves have provided clues to its function. In a rat model, the synthesis of apoE
increases 250- to 350-fold following peripheral nerve injury (Ignatius et al., 1986; Snipes
et al., 1986). This enormous increase of apoE is thought to play a key role in recycling

lipids from the degenerating axonal and myelin membranes for use by regenerating axons
and myelin sheaths. Similarly, induction of apoE synthesis has also been observed in the
central nervous system following optic nerve and spinal cord injury (Ignatius et al., 1986;
Messmer et al., 1996; Snipes et al., 1986). Studies on apoE-deficient mice showed fewer
synapses, vacuolized and swollen dendrites, and a reduced recovery following perforant
pathway lesions (Masliah et al., 1995; Masliah et al., 1996; Masliah et al., 1997).
Conversely, studies from other laboratories did not observe any significant morphological
abnormalities in apoE gene knockout (KO) mice (Gandy et al., 1995; Anderson et al.,
1998). Another study found that apoE may not be required for the maintenance of the
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basal forebrain cholinergic neurons, but it may play a role in their repair following brain
injury (Fagan et al., 1998). The reason for the discrepancy is not clear; however,
differences in the strain, age, and sex of mice used may have contributed to the data
inconsistencies.
In contrast to the morphological studies, behavioral studies have consistently
shown that the apoE-KO animals exhibit spatial learning deficits (Masliah et al., 1996;
Gordon et al., 1996). Infusion of recombinant apoE into the lateral ventricles of apoE
KO mice reversed behavioral and morphological anomalies (Masliah et al., 1996). Other
studies involving apoE KO mice have suggested that apoE may be involved in protecting
the brain against acute injury (Chen et al., 1997). These results provide convincing
evidence that apoE plays a critical role in neuroprotection, preservation and plasticity
within the CNS.
Evidence Linking apoE to Alzheimer's Disease
Increased apoE immunoreactivity is present in the brains of patients with such
neurological diseases as Creutzfeldt-Jacob disease, Down's syndrome and Alzheimer's
disease (AD) (Namba et al., 1991). In addition a recent study suggest the apoE4 allele
may be involved with the onset of Parkinson's disease (Zareparsi et al., 2002).
AD is characterized by the presence of senile (neuritic) plaques, amyloid
angiopathy, and neurofibrillary tangles (Cotran et al., 1999). The neuritic plaques are
focal, spherical collections of dilated, tortuous, silver-staining neuritic processes
(dystrophic neurites) surrounding a central amyloid core, often surrounded by a clear
halo. The dominant component of the plaque core is amyloid beta, a peptide of
approximately 40-to 43-amino acid residues derived from a larger molecule, amyloid
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precursor protein (APP) (Cotran et al., 1999). The neuritic components often colocalize
with both APP and growth associated protein (GAP) 43, suggesting that they may
represent aberrant sprouting of neurons (Masliah et al., 1992). Neurofibrillary tangles are
intracellular and contain paired helical filaments along with some straight filaments that
appear to have comparable composition. These filaments are composed of
hyperphosphorylated tau (Cotran et al., 1999). ApoE fragments have been shown to
induce intracellular neurofibrillary tangles in cultured neurons with truncated apoE4
inducing more inclusions than truncated apoE3 (Huang et al., 2001 ). The deposition of
tau in the brains of Alzheimer's disease patients is related to the amount of Abeta40 and
the presence of apoE4 allele (Mann et al., 2002). The role of the plaques and tangles in
the etiology of AD is still unclear.
There are three forms of AD: early-onset familial, late-onset familial, and lateonset sporadic. Early-onset AD represents approximately 5% of patients, whereas lateonset AD accounts for a majority of AD cases. Accumulating data demonstrates a strong
association of the apoE4 allele with late-onset familial AD (Corder et al., 1993; Mayeux
et al., 1993; Rebeck et al., 1993; Sanders et al., 1993). The apoE4 allele is greatly overrepresented in late-onset familial AD subjects (52%) versus controls (16%), and the risk
of AD in individuals homozygous for apoE4 is over five times that of homozygous apoE3
individuals (Coder et al., 1993). Moreover, AD patients with apoE4 alleles usually show
an earlier age of onset and a more rapid progression of the disease (Bennet et al., 1995).
These findings suggest a causal link between apoE polymorphism and the development
of AD; again, the mechanism behind the pathological effects of the apoE polymorphism
remains unknown (Roses et al., 1994).
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Effect of apoE on Neurite Outgrowth
Previous findings suggest that apoE4 may contribute to AD by inhibiting neurite
outgrowth (Bellosta et al., 1995; Mahley et al., 1996; Nathan et al., 1994; Nathan et al.,
1995). Incubation of primary dorsal root ganglion neurons or Neuro-2a cells, a murine
neuroblastoma cell line, with apoE3 or apoE4 together with either plasma lipoproteins or
CSF lipoproteins, resulted in dramatic isoform-specific effects. In both neuronal cell
culture systems, apoE3 increased neurite outgrowth, whereas apoE4 stunted outgrowth
(Nathan et al., 1994; Nathan et al., 1995). In these studies, the apoE isoforms also
affected the cytoskeleton. Cells treated with lipoproteins and apoE4 showed fewer
microtubules as compared with cells grown in medium alone, in medium containing
lipoproteins, or in medium containing lipoproteins and apoE3 (Nathan et al., 1995).
These effects of apoE on neurite outgrowth appear to be lipoprotein receptor-mediated.
Free apoE, which is not a ligand for lipoprotein receptors, does not mediate the effect in
the absence oflipoproteins (Bellosta, 1995; Nathan et al., 1995). The in vitro data
therefore demonstrate that apoE has a tremendous impact on the structure and function of
cultured PNS neurons.
Basic Structure of the Olfactory System
The olfactory epithelium is made up of an epithelium and a mucosal layer (figure
1). The olfactory receptor neurons (ORN) reside in a pseudostratified epithelium on the
nasal turbinates. Basal cells lie at the base of the epithelium and are critical because they
divide and form new olfactory neurons. Sustentacular cells are distributed throughout the
epithelium. They help detoxify chemicals that come into contact with the epithelium.
The axons from the olfactory neurons collect in bundles and form the olfactory nerve.
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The nerve exits the nasal cavity, passes through the cribriform plate, and terminates in the
glomeruli of the olfactory bulb.
The olfactory bulb develops from the telencephalon, and is, therefore, a part of the
cerebral hemispheres. It is the first CNS relay for olfactory input. The bulb is organized
in concentric laminae each with characteristic cell types and synaptic connectivity (figure
2). The most peripheral layer is the olfactory nerve layer. It is composed of the axons of
the ORN, sheathing glia and microglia. The olfactory receptor axons terminate in the
glomerular layer, synapsing on the dendrites of mitral cells in structures termed
glomeruli. Internal to the glomerular layer is the external plexiform layer, which is a cell
poor zone containing the dendrites of mitral cells and other interneurons. The cell bodies
of the mitral cells, the principal projection neurons of the olfactory bulb, are located in a
distinct monolayer between the external plexiform layer and granular cell layer. The
granular cell layer is principally composed of small interneurons, called granule cells,
whose dendrites ramify in the external plexiform layer. Apart from the granule cells, the
bulb also contains two other interneurons, tufted cells, in the external plexiform layer,
and periglomerular cells, surrounding the glomeruli.
Olfactory Nerve Regeneration
Verhaagen and coworkers induced reversible lesions of the olfactory epithelium
and olfactory nerve with Triton X-100 (TX-100) and characterized the process of
regeneration in mice (Verhaagen et al., 1989; Verhaagen et al., 1990). Intranasal
irrigation ofTX-100 in mice causes rapid retrograde degeneration of the ORN in the
epithelium, with orthograde degeneration of their synaptic terminals in the bulb while
sparing the basal cells. The degenerative process is completed during the first week

6

following lesioning. Verhaagen and coworkers identified two stages in the regeneration
process of olfactory neurons. The first stage starts with the basal cells proliferating at
about three days post-lesioning. These newly formed neurons expressed GAP 43, a
phosphoprotein related to neuronal growth and plasticity. New axons reach the olfactory
nerve layer at one to two weeks, and at three weeks, neurons are visible in the glomeruli.
The second stage begins when the neurons reach the glomeruli. This stage is marked by
a decrease in the expression of GAP43 and an increase in the expression of olfactory
marker protein (OMP), a protein of unknown function present only in mature neurons.
The entire process is complete at six to seven weeks (Cummings et al., 2000).
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Goals and Hypotheses
I. To examine the distribution of apoE in the mouse olfactory bulb. I hypothesized
that apoE would be expressed in areas of nerve degeneration and regeneration.
2. To examine the distribution of apoE in the olfactory bulb following olfactory
nerve lesion. I hypothesized that apoE would be transiently increased following
olfactory nerve lesion.
3. To examine the effects of apoE deficiency in olfactory nerve regeneration. I
hypothesized that apoE deficient mice would have delayed olfactory nerve
regeneration as compared to wild type mice.
4. To investigate the effects of human apoE4 and human apoE3 genes in olfactory
nerve regeneration. I hypothesized nerve recovery would follow the order: 1.
wild-type, 2. apoE3, 3. apoE4, 4. apoE-KO.

8

EXPERIMENT I: APOLIPOPROTIEN E IMMUNOREACTIVITY IN MOUSE
OLFACTORY BULB
Materials and Methods

To examine the distribution of apoE-like immunoreactivity in mice, wild-type
(WT) and apoE KO mice (C57BL/6J, males, 4 months old) were purchased from

Jackson, Bar Harbor, ME. Mice were anesthetized with sodium pentobarbital (80
mg/kg), transcardially perfused with cold saline (0.9°/o NaCl) and then with 4%
paraformaldehyde in 0.1 M phosphate buffered saline, pH 7.4 (PBS). Olfactory bulbs
were removed and post-fixed in buffered :fixative for two hours. Following the :fixation,
olfactory bulbs were cryoprotected overnight in 30% sucrose in 0.1 M phosphate buffer.
After cryoprotection, the bulbs were frozen with dry ice and sections were cut on a
cryostat at 30 µm. Sections were incubated in 5% dried milk in 0.1 M PBS for 1 h, then
incubated for 48 h with anti-apoE polyclonal goat primary antisera (Calbiochem) at
1:16,000 dilution in PBS. The sections were then incubated in rabbit-anti-goat solution
(1 :200 dilution; Cappel) for 1 h, rinsed three times with PBS, then peroxidase-antiperoxidase complex (1: 100 dilution; Sternberger) for 1 h. The immunoreactive product
was nickel-intensified (Benzing et al., 1995). Diaminobenzidine (DAB) (0.05% with
0.01% ofH202) was used directly for development. ApoE KO mice were processed in
parallel with normal mice.
Results

ApoE-like immunoreactivity was clearly present in the mouse olfactory nerve
layer, where the large fascicles of olfactory nerve were often, but not always, outlined by
immunoreactive product (figure 3, A and B). Cellular processes could be consistently
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seen in the olfactoiy nerve and these appeared to be glial, although the type of glia was
not ascertained. Glomeruli were weakly immunostained, but were clearly outlined by
reaction product in the septae surrounding the glomeruli (figure 3, A and B).
Jmmunostaining was in cellular processes of what appear to be glai although a neuronal
source was not ruled out. Immunoreactivity in this periglomerular region was more
intense than in the EPL. The EPL, although less intensely immunostained that the
periglomerular region, did display lamination with the external part adjacent to glomeruli
more immunoreactive that the internal part. The internal plexiform layer, just beneath the
mitral cell layer, was obviously stained more intensely than the EPL or GCL. In addition,
the core of the subependymal layer was intensely immunostained. A complete absence of
staining in the apoE KO mice confirmed that we were visualizing apoE-like
immunoreactivity.
Discussion
This study identifies apoE-like immunoreactivity surrounding olfactoiy nerves
and glomeruli in normal olfactoiy bulbs in mice. Glia in this active region elaborate both
trophic and inhibitory growth factors (Ramon-Cueto et al., 1995). Moreover, glia
probably participate both in the recycling of membrane constituents of degenerating
olfactory nerve fibers and the facilitation of axonal elongation and neuropil
reorganization associated with regeneration. Therefore, apoE present in this region may
be involved with either degeneration or regeneration of axons.
The distribution of olfactoiy bulb apoE is not spatially congruent with GAP43
which is a 25 kD protein that is associated with axonal growth cones and preterminal
axons in the olfactoiy bulb (Ramakers et al., 1992; Verhaagen et al., 1989). Both the
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glomerular zone and granule cell layer are rich in GAP43 immunoreactivity (Ramakers et

al., 1992; Struble et al., 1998; Verhaagen et al., 1989), but apoE is primarily found in the
gtomerular zone with markedly less immunoreactivity present in the granule cell layer.
This observation suggests that apoE is not simply related to axonal growth. The olfactory
bulb might be an ideal structure for determining the role of apoE in regeneration or
degeneration in light of the ability of the olfactory nerve to regenerate and the availability
to reversibly lesion the nerve.
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EXPERIMENT II: APOLIPOPROTEIN EIS UPREGULATED IN OLFACTORY
BULB GLIA FOLLOWING PERIPHERAL RECEPTOR LESION IN MICE
Material and Methods
Two- to four-month-old C57BL/6J mice (Jackson, Bar Harbor, ME) were
lesioned as previously described (Margolis et al., 1974; Rochel et al., 1980; Verhaagen et
al., 1989). Briefly, a 25-gauge needle with a rounded tip, was inserted approximately 2
mm into one nostril, and 100 µl of 0. 7 % TX-100 in saline, or 100 µl of saline alone was
irrigated into a nostril of unanesthetized mice. This technique results in extensive
bilateral damage to the olfactory epithelium with approximately 70-800/o of the olfactory
epithelium lesioned (Nathan and Struble, personal observation). This procedure spares
the basal cells which subsequently divide and differentiate into new ORN (Margolis et
al., 1974; Rochel et al., 1980; Verhaagen et al., 1990). Mice were sacrificed at days 0, 3,
7, 14, 28, 44 and 56 days post-treatment (n=3 mice treated with TX-100 at each time
point and one mouse at each time point treated with saline alone).
Following the survival periods after TX-100- or saline-irrigation, mice were
anesthetized with pentobarbital (80mg/kg), and perfused transcardially with cold saline
and then with 4% paraformaldehyde in 0.1 M PBS, pH 7.4. Olfactory bulbs were
removed and post-fixed in buffered fixative for two hours. Following the fixation,
olfactory bulbs were cryoprotected overnight in 30% sucrose in 0.1 M phosphate buffer.
After cryoprotection, the bulbs were frozen with dry ice and sections were cut on a
cryostat at 30 µm. Sections were incubated in 5% dried milk in 0.1 M PBS for 1 h, then
incubated for 48 h with anti-apoE polyclonal goat primary antisera (Calbiochem) at
1: 16,000 dilution in PBS. The sections were then incubated in rabbit-anti-goat solution
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(1 :200 dilution; Cappel) for 1 h, rinsed three times with PBS, then peroxidase-antiperoxidase complex (1 :200 dilution; Sternberger) for 1 h. The immunoreactive product
was nickel-intensified (Benzing et al., 1995). DAB (0.05% with 0.01% ofH202) was
used directly for development.
To determine the glial cell type expressing apoE, double label
immunocytochemistry was performed on olfactory bulb sections obtained from mice
sacrificed at three and seven days post-nerve lesion or saline treatment. This double
labeling technique uses sequential reactions with antisera and reaction products of DAB
and benzidine dihydrochloride (BDHC) (Levey et al., 1986). In our hands BDHC is not
nearly so sensitive as DAB as a chromogen, however, we purposely selected chromogens
that were easy to discriminate. DAB results in a diffuse brown product and BDHC
presents a granular blue reaction product. Hence, we could identify colocalization on the
basis of both color and appearance. Although probably less sensitive than other
techniques, the granular deposition of BDHC allowed unequivocal identification of cell
types expressing apoE. Sections were initially processed for demonstrating apoE with
goat antisera at 1:8 000 dilution overnight followed by rabbit-anti-goat serum (1 :200
dilution; Cappel) and then goat peroxidase-anti-peroxidase (1 :200 dilution; Sternberger).
DAB (0.05% with 0.01% ofH202) was used directly for development. Some sections
were removed and mounted directly on slides. The remainder of the sections were
reacted overnight with either monoclonal anti- mouse F4/80 (1 :400 dilution; Serotec), an
antigen expressed by activated microglia, (Andersson et al., 1991) or monoclonal
antibody to GFAP (1:4,000 dilution, Accurate). These sections were then developed with
0.01% BDHC. The following controls were included to assure specificity (Levey et al.,
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l986). 1) Sections were immunoreacted for the initial antigen (apoE), developed with
DAB then reacted with BDHC in the absence of the secondary antibody. 2) The initial
jmmunohistochemical steps to visualize apoE were omitted, the sections were reacted
with DAB, and then the sections were immunoreacted for the second antigen (either
F4/80 or GFAP). Changing the order of antisera (i.e., reacting first for GFAP or F4/80)
was not feasible because the BDHC technique was not sensitive enough to reliably
identify apoE immunoreactive perikarya in unlesioned mice.
To determine the distribution of apoE immunostained cells, sections form at least
two mice, at ages up to 14 days, were reacted with DAB as the chromogen. Plotting of
apoE-immunostained cells in these sections was performed with Neurolucida, which
permits operator selection of marked objects on a live microscopic image. The lamina
were outlined at low power (2x objective) then each immunostained perikarya was
marked at higher power (20x objective). Areas of the section and cell counts were used
to obtain a rough estimate of cell density.

Results
lmmunocytochemical studies of saline treated mice displayed the previously
described distribution of apoE-like immunoreactivity (Struble et al., 1999). Most apoE
immunoreactivity in saline treated mice was diffusely present in the neuropil, primarily
surrounding glomeruli. Few apoE immunoreactive cell bodies were visible and most of
these were found in the glomerular layer (figure 4). Three days following TX-100 lesion,
the olfactory nerve showed intense immunostaining for apoE although the glomeruli
displayed about the same intensity ofimmunostaining as in the control mice (figure 5).
Seven days following lesion, apoE continued to show intense staining in the olfactory
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nerve and also showed glomerular immunoreactivity (figure 6). At 14 days, apoE-like
imJDunoreactivity increased in the glomeruli to bring intensity levels comparable to that
of the external plexiform layer (figure 7). By 28 days post-lesion, the apoE
immunoreactivity was similar the non-lesioned mice (figure 8).
Colocalization studies at three and seven days following lesion showed that apoE
was expressed by both astroglia expressing GFAP and microglia expressing
immunoreactivity identified by F4/80 (figure 9). The granular/crystalline BDHC reaction
product ofGFAP or F4/80 was commonly associated with depositions of the more
uniform DAB reaction product representing apoE. These observations show that both
astroglia and microglia are associated with apoE.
Plotting of apoE-immunoreactive cells generally supported these conclusions.
Although only two sections were available for each time period, the pattern was virtually
identical between the sections at each age. In saline treated mice the density of visible
apoE immunoreactive cells was about l 8/mm2 and theses cells were primarily in the
glomerular layer. At three days after lesion immunoreactive cell bodies could be seen
throughout the olfactory bulb including the external plexiform and granule cell layer. In
this case, the density ofidentifiable cells was 253/mm2 . The cells containing apoE-like
immunoreactivity appeared to be glia. At seven days, the olfactory nerve had
degenerated, and apoE immunoreactive somata were seen primarily in the periglomerular
region and a rough density of l l 9/mm2 . By 14 days, overall immunostaining for apoElike immunoreactivity appeared to be increased throughout the olfactory bulb and density

in this section was 27/mm2 . Most of these immunoreactive perikarya were present in the
glomerular layer. By 42-56 days, no differences in the numbers of visible cells could be
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seen between the control and lesioned mice. At no time did we observe apoE-like
iJDmunoreactivity in unequivocally recognized neurons.

Discussion
Degeneration and regeneration in the olfactory bulb following olfactory nerve
lesion in this study replicates previous reports in mice (Rochel et al., 1980; Verhaagen et
al., 1990; Graziadei et al., 1983; Harding et al., 1977; Nadi et al., 1981; Verhaagen et al.,
1989) and rats (Schwob et al., 1995; Ravi et al., 1997; Deamer et al., 1995; Genter et al.,
1994). OMP in the olfactory bulb declines slightly at three days following olfactory
epithelium lesion, and fully by seven days, representing the degeneration of the ORN
terminals. Olfactory nerve terminals were still present in the glomeruli at three days and
immunoreact for either amyloid precursor protein-like immunoreactivity (Struble et al.,
1998) or OMP (Struble and Nathan, personal observation). Within several days, the
olfactory epithelium begins to regenerate from stem cells (Schwob et al., 1995; Graziadei
et al., 1979). Progeny of these stem cells differentiate into new ORN, and grow axons
into olfactory bulb to re-innervate glomeruli between 14 to 21 days (Schwob et al., 1999).
Consequently these studies provide a framework for analyzing apoE expression in the
temporal sequence of events in the regeneration process.
ApoE elevation is correlated with olfactory nerve degeneration and regeneration.
lmmunocytochemical observations of intense apoE-like immunoreactivity on the nerve
and an increased number of visible perikarya in the glomerular layer support this
interpretation. Glomeruli were only weakly immunoreactive at 3 days, when fibers are

still present in the glomeruli (Struble et al., 1998), but intensity had increased by seven
days and apoE levels were still elevated at 21 days. This pattern of apoE expression is
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basically the reverse of OMP expression in the bulb following olfactory epithelium

lesion. As OMP levels recovered, apoE levels declined.
Plotting of apoE immunoreactive perikarya raise several interesting questions,
although these studies were not designed to rigorously evaluate density. Increased
numbers of immunoreactive perikarya are seen throughout the olfactory bulb and total
cell number is 10-fold that in control tissue at three days. In contrast, total apoE (by
western blot) is only 2 fold of saline treated levels (Nisar, 1999). Furthermore, whole
bulb levels of apoE remain elevated for 14 to 21 days, but the plotting results show that
the number of visible apoE-immunoreactive perikarya rapidly decline to essentially
normal levels by 14 days.
Part of the explanation for this discrepancy may be in the difficulty of localization
of apoE. In our hand, apoE immunoreactivity in the nonnal mice olfactory bulb is
diffuse; visible apoE-immunoreactive perikarya were very rare. Procedures to increase
the intensity of perikaryal staining also raised the "background" similarly, suggesting that
apoE immunoreactivity is primarily present either in small processes or extracellularly.
This discrepancy between the density of apoE immunoreactive cells and whole bulb
immunoreactivity probably represents the localization of apoE in the neuropil. These
data suggest that initially glia produce apoE (hence a perikaryal localization) but it is
rapidly translocated to an extracellular compartment. Neurons apparently are not a major
source for apoE production. The mitral neurons are found in single laminae in the bulb
and it is highly unlikely that we would not have seen a labeled cell. This suggests that
intraneuronal apoE concentration in vivo is below the threshold of detectability by
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jmmunocytochemical techniques. Hence, neuronal translocation of apoE and associated
lipids is comparatively small or brief
Translocation apparently occurs in the PNS. Resident macrophages and
monocyte-derived macrophages, at the site of injury, are reported to be the primary
sources of the large quantities of apoE-containing lipoproteins (Boyles et al., 1985).
These lipoprotein particles probably scavenge cholesterol released from degenerating
myelin. Scavenged cholesterol was subsequently used in membrane biosynthesis by
growth cones of sprouting axons by the low-density lipoprotein (LDL) receptor-mediated
endocytosis (Mahley, 1988). Reactive gliosis in the CNS may by a central equivalent of
macrophage activity in the PNS.
Reactive gliosis appears to parallel apoE expression. Several studies have
reported intense reactive astrogliosis within three to seven days of nerve lesion both
around olfactory glomeruli and also throughout the olfactory bulb (Schwob et al., 1999;
Struble et al., 1999; Deamer et al., 1995; Anders et al., 1990). Furthermore astroglial
markers are elevated in the olfactory bulb for at least 2 to 4 weeks following lesion.
These data suggest that processes related to degeneration continue for several weeks
following nerve lesion. A previous study suggested that apoE might be involved in
regeneration because hippocampal elevation of apoE mRNA trail that of GFAP following
perforant path lesion (Poirier et al., 1991). These data are not contradictory. If astroglia
and microglia must be activated before they produce apoE, this temporal relationship is
logical.
The double labeling immunocytochemical studies confirmed that both reactive
astroglia and microglia produce amounts of apoE following a lesion. It is probably fairly
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safe to further suggest that apoE is produced by activated microglia. In vitro studies have
shown apoE production by microglia, but in vivo studies have been equivocal (Boyles et
al., 1985; Nakai et al., 1996; Uchihara et al., 1995; Fujita et al., 1999). This difference
may represent a detection problem perhaps related to the "activated" status of astroglia
and microglia. I was unable to unequivocally colocalize apoE and the microglail marker

in non-lesioned mice, although I did identify GFAP-apoE co-localization in the same
mice. Only following olfactory nerve lesion, when whole bulb levels of apoE increased
1.5 to 2-fold was the level of apoE high enough to detect when I used combined labeling

with DAB and BDHC. Nonetheless, it would seem logical that detection of apoE in
microglia may require up-regulation of both microglial antigen (F4/80) that occurs after
lesion (Anderssen et al., 1991) and cellular localization of apoE. Our data show that both
microglia and astroglia produce apoE in the olfactory bulb but activation of glia might be
required for co-localization.
A hypothesis of injury-induced apoE production may explain variable
morphological effects observed in the absence of the apoE gene. In vitro, apoE, but only
in combination with a source oflipids, facilitates process growth (Nathan et al., 1994). I
propose that in vivo apoE is transiently increased to scavenge lipids released form
degenerating processes, and then provides those lipids to regenerating processes. Much
of this lipid is postulated to come from degenerating myelin sheaths (Mahley et al.,
1996). In the intact central nervous system, inefficient recovery may not be apparent, or
perhaps could be compensated for by other less efficient apolipoproteins (Terrisse et al.,
1998).
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A hypothesis of apoE participation in lipoprotein recycling is also compatible

with previous observations of the effects of apoE alleles in both AD and recovery form

bead injury. The apoE4 allele not only predisposes to AD, but also substantially
increases the risk of developing AD after head trauma (Mayeux et al., 1995). Moreover,
patients with the apoE4 allele manifest a poorer outcome following traumatic brain injury
(Jordan et al., 1997), and boxers with the E4 allele were at much greater risk to develop
chronic neurologic deficits than those not having the E4 allele (Jordan et al., 1997).
Recently, it was suggested that blood-flow (measured by £MRI) in individuals with
apoE4 allele may be greater than apoE3 homozygotes while performing the same task
(Bookheimer et al., 2000) suggesting some level of inefficiency in learning. If apoE is
involved in efficient recycling or redistribution of lipoproteins during brain function or
following injury, a lifetime of inefficient functioning may results in an accentuation of
mild dysfunction and an increased risk for dementia.
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EXPERIMENT ill: DELAYED OLFACTORY NERVE REGENERATION IN
APOE-DEFICIENT MICE.
Materials and Methods
Breeding pairs of homozygous apoE KO mice that have been back-crossed at
least 10 times to the C57BL/6J wild-type mice (Jackson, Bar Harbor, ME). ApoE
genotype of the litters were verified by PCR and confirmed by immunoblot using antiapoE (1: 1000; Calbiochem).
Two- to four-month-old apoE KO and wild type mice were lesioned as previously
described (Margolis et al., 1974; Rochel et al., 1980; Verhaagen et al., 1990). Briefly, a
25-gauge needle with a rounded tip, was inserted approximately 2 mm into one nostril,
and 100 µl of0.7% TX-100 in saline or 100 µl of saline alone was irrigated into a nostril
of unanesthetized mice. This technique results in extensive bilateral damage to the
olfactory epithelium with approximately 70-80% of the adult olfactory epithelium
lesioned (Nathan and Struble, personal observation). This procedure spares the basal
cells, which subsequently divide and differentiate into new ORN (Margolis et al., 1974;
Rochel et al., 1980; Verhaagen et al., 1990). Mice were sacrificed at days 0, 3, 7, 14, 21,
42 and 56 days post-treatment (n=3 animals for each time point and treatment).
Following the survival periods after TX-100 or saline irrigation, mice were
anesthetized with pentobarbital (80 mg/kg), and perfused transcardially with cold saline
and then with 4% paraformaldehyde in 0.1 M phosphate buffer. Olfactory bulbs were
post-fixed in buffered fixative for two hours. Following the fixation, olfactory bulbs
were cryoprotected overnight in 30% sucrose in 0.1 M phosphate buffer. After
cryoprotection, the bulbs were frozen with dry ice and sections were cut on a cryostat at
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30 µm. Sections were incubated in 5% dried milk in 0.1 M PBS for 1 h. Sections were
then incubated for 48 h with anti-OMP polyclonal goat primary antisera (gift from Frank
Margolis, Ph.D., University of Maryland) at 1 :4,800 dilution in PBS. The sections were
then incubated in rabbit-anti-goat solution (I :200 dilution; Cappel) for 1 h, rinsed three
times with PBS, then goat peroxidase-anti-peroxidase complex (1:200 dilution;
Sternberger) for 1 h. DAB (0.05% with 0.01% ofH202) was used directly for
development.

Results

OMP
Day 3 Saline Treated: The WT-SA and KO-SA mice both showed intense
immunoreactivity in the olfactory nerves and the glomerular layer. No differences were
seen between the two groups.
Day 3 TX-100 Treated: The WT-TX mice (figure 10) and KO-TX mice (figure 11)
showed intense immunoreactivity in the olfactory nerves. The WT-TX mice showed
moderate immunoreactivity in the glomerular layer while the KO-TX mice showed light
staining in the glomerular layer.
Because the WT-SA and KO-SA mice both showed the typical immunoreactivity
seen in untreated WT mice, we decided not to immunostain the WT-SA mice on days 7,
21and56.
Day 7 Saline Treated: The KO-SA mice showed intense immunoreactivity in the
olfactory nerve and glomerular layer. This immunoreactivity was the same as the KO-SA
and WT-SA mice further supporting our idea not to stain the WT-SA mice on days 7, 21
and 56.
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Day 7 TX-100 Treated: The WT-TX mice showed intense immunoreactivity in the
olfactory nerve and moderate immunoreactivity in the glomerular layer. The KO-TX
mice showed light to moderate immunoreactivity in the olfactory nerve and glomerular
layer.
Day 21 Saline Treated: The KO-SA mice showed dark olfactory nerve immunoreactivity
and moderate, well organized glomerular immunoreactivity.
Day 21 TX-100 Treated: The WT-TX mice (figure 12) showed strong immunoreactivity
in the olfactory nerve and moderate immunoreactivity in the glomerular layer. The
glomeruli were decreased in number but appeared well organized. The KO-TX mice
(figure 13) had moderate immunoreactivity in the olfactory nerve and glomerular layer;
however, the glomeruli were unorganized.
Day 42 Saline Treated: All of the 42-day mice were overall lightly staining. The WT-SA
and KO-SA showed light immunoreactivity in the olfactory nerve and glomerular layer.
Day 42 TX-100 Treated: The glomeruli in the WT-TX mice were not as numerous as in
the saline treated mice; however the immunoreactivity was the same. The KO-TX mice
showed light immunoreactivity in the olfactory nerve, similar to the other 42-day mice.
The glomerular layer was also lightly stained, but the glomeruli were smaller compared
to the other 42-day mice.
Because the 42-day WT-TX mice showed almost complete recovery from
olfactory nerve lesion, no WT mice were stained on day 56.
Day 56 Saline Treated: All of the 56-day mice were overall lightly staining. The KO-SA
mice showed a light immunoreactivity in the olfactory nerve and glomerular layer. In
addition, the glomeruli were small and unorganized.
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Day 56 TX-I 00 Treated: The KO-TX mice showed light staining in the olfactory nerve
and glomerular layer. Similar the 56-day KO-SA mice, the glomeruli were unorganized.
In addition, the glomeruli were sparse and incompletely stained.

Discussion
On days 3 and 7, there was a loss ofOMP immunoreactivity. This represents
degeneration of olfactory nerve after lesion. By day 21, there was an increase in OMP
immunoreactivity in the WT-TX mice. This reactivity showed that some of the axons

had already reached the glomerular layer. The KO-TX mice did not have the same
immunoreactive pattern as the WT-TX mice. KO-TX mice did not show the same
pattern of mature olfactory neurons in the glomerular layer, as seen by OMP
immunoreactivity. By day 42 the WT-TX mice appeared to be almost fully recovered
from the lesion. In comparison the KO-TX mice had not recovered. OMP
immunoreactivity was still poor at 56-days in the KO-TX mice representing a lack of
neurons reaching the glomerular layer and forming mature synapses. In conclusion, it
appeared that the absence of an apoE gene greatly diminishes the ability of the olfactory
nerve to regenerate following lesion.
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EXPERIMENT IV: EFFECTS OF HUMAN APOLIPOPROTEIN E ISOFORMS
ON OLFACTORY NERVE PLASTICITY IN MICE
Materials and Methods

Two- to four-month-old male WT, apoE KO and transgenic mice (gift from David
Holtzman, M.D., Washington University) were used for this study. The transgenic mice
were apoE KO mice that had either a human apoE3 gene or a human apoE4 gene inserted
under a GFAP promoter (Sun et al., 1998). Mice were lesioned as previously described
(Margolis et al., 1974; Rochel et al., 1980; Verhaagen et al., 1990). Briefly, a 25-gauge
needle with a rounded tip, was inserted approximately 2 mm into one nostril, and 100 µl
of0.7 % TX-100 in saline, or 100 µl of saline alone was irrigated into a nostril of
unanesthetized mice. This technique results in extensive bilateral damage to the olfactory
epithelium with approximately 70-800/o of the adult olfactory epithelium lesioned (Nathan
and Struble, personal observation). This procedure spares the basal cells which
subsequently divide and differentiate into new ORN (Margolis et al., 1974; Rochel et al.,
1980; Verhaagen, et al., 1990).
Mice were sacrificed at 14 days post-treatment which is the midpoint of olfactory
nerve regeneration (n=3 mice for each genotype and treatment). Mice were anesthetized
with pentobarbital (80 mg/kg), and perfused transcardially with cold saline and then with
4% paraformaldehyde in 0.1 M phosphate buffer. Olfactory bulbs were post-fixed in
buffered fixative for two hours. Following the fixation, olfactory bulbs were
cryoprotected overnight in 300/o sucrose in 0.1 M phosphate buffer. After cryoprotection,
the bulbs were frozen with dry ice and sections were cut on a cryostat at 30 µm. Sections
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were incubated in 5% dried milk in 0.1 M PBS for 1 h. Each mouse olfactory bulb was
assessed for five antigens as follows:
1. Anti-GFAP monoclonal mouse antibody (1:4,000 dilution; Accurate) 48 h incubation
2. Anti-apoE polyclonal goat antibody (1:8,000 dilution; Calbiochem) 24 h incubation
3. Anti-F4/80 monoclonal mouse antibody (1 :400 dilution; Serotec) 24 h incubation
4. Anti-OMP polyclonal goat antibody (1 :4,800 dilution; gift from Frank Margolis,
Ph.D., University of Maryland) 24 h incubation
5. Anti-Synaptophysin monoclonal mouse antibody (1:500 dilution; Boehringer
Mannheim) 48 h incubation
To visualize GFAP and Synaptophysin, sections were incubated in goat-anti-mouse
solution (1 :200 dilution; Cappel) for 1 h, and for OMP and apoE, sections were incubated
in rabbit-anti-goat solution (1 :200 dilution; Cappel) for 1 h. All sections were rinsed
three times with PBS, then treated with either mouse or goat peroxidase-anti-peroxidase
complex (1:200 dilution; Sternberger) for 1 h. DAB (0.05% with 0.01% H202) was used
directly for development. An avidin/biotin (yectastain ABC kit, Vector) technique was
used with DAB to visualize F4/80 binding.

Results
GFAP
Saline Treated: No differences were seen between the WT-SA (figure 14), apoE3-SA,
apoE4-SA and apoE-KO-SA groups. In general, immunoreactivity was more intense in
the glomeruli.
TX-100 Treated: The WT-TX (figure 15) and apoE-KO mice (figure 16) showed heavy
immunoreactivity in the glomerular layer as well as a general increase in
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immunoreactivity in the olfactory bulb. ApoE3-TX and apoE4-TX mice (figure 17)
demonstrated immunoreactivity in the glomerular layer, but lacked the increased
immunoreactivity in the external plexiform layer characteristic of the WT-TX and apoEKO mice.
Summary: Following lesion GFAP-immunoreactivity in apoE3-TX and apoE4-TX mice
did not appear to be increased throughout the bulb so much as it did in the WT-TX and
apoE-KO mice. The absence of a normally regulated apoE gene affected expression of
the GFAP gene. The failure to identify clear upregulation of immunoreactivity in the
apoE3-TX and apoE4-TX mice may represent a ceiling effect or some interaction with
the an abnormally regulated apoE gene.

ApoE
Saline Treated: The WT-SA mice (figure 18) showed diffuse immunoreactive pattern in
the olfactory nerve and in the periglomerular layer, which, in turn showed more
immunoreactivity than the glomerular layer. Only astroglial-like cell body staining in the
glomerular layer was seen in the apoE3-SA and apoE3-SA mice (figure 19), and the core
of the glomeruli were immunoreactive and darker than the rest of the bulb. There was no
immunoreactivity in the KO-SA mice.
TX-100 Treated: The WT-TX mice (figure 20) showed increased apoE immunoreactivity
in the periglomerular layer. ApoE4-TX mice and apoE3-TX mice (figure 21) showed no
increase in immunoreactivity. There was no immunoreactivity in the apoE-KO-TX mice.
Summary: The levels of apoE are increased following lesion in the WT-TX mice;
however, in the apoE3-TX and apoE4-TX groups apoE immunoreactivity is not increased
following lesion.
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F4/80

Saline Treated: No differences were seen between the apoE-KO-SA, apoE3-SA, apoE4SA and WT-SA mice (figure 22). In general, there was moderate diffuse
immunoreactivity in the glomerular layer and external plexiform layer with a lamination
between these two layers.
TX-100 Treated: The WT-TX mice (23) and apoE-KO-TX mice (figure 24) showed
increased immunoreactivity in the glomerular layer and external plexiform layer
compared to the transgenic mice (figure 25).
Summaiy: The expression of either the apoE3 or apoE4 inserted gene apparently turns
down or blocks activation of microglia.

OMP
Saline Treated: No differences were seen between the apoE-KO-SA , apoE3-SA, apoE4SA and WT-SA mice (figure 26). In general, the olfactory nerve and glomerular layer
showed intense immunoreactivity.
TX-100 Treated: Immunoreactivity in the WT-TX mice (figure 27) showed smaller
glomeruli than in the SA treated mice. The apoE4-TX and apoE3-TX mice (figure 28)
both showed less glomerular staining than the WT-TX mice. The KO-TX mice (figure
29) showed less staining in the glomeruli than the transgenic mice.
Summaiy: Recovery appeared to follow the order of WT-TX, apoE3-TX or apoE4-TX
and apoE-KO-TX. Apparently the presence of either the apoE3 or apoE4 gene can
partially compensate for the absence of the WT gene.
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Synaptophysin

Saline Treated: No differences were seen between the apoE-KO-SA, apoE3-SA, apoE4WT-SA mice (figure 30). In general, there is intense immunoreactivity in the glomerular
layer and lighter immunoreactivity in the external plexiform layer.
TX-100 Treated: The WT-TX mice (figure 31) had a general attenuation of
immunoreactivity and smaller glomeruli compared to SA treated mice. Immunoreactivity
in the apoE3-TX and apoE4-TX mice (figure 32) showed smaller and lighter glomeruli
than seen in the WT-TX mice. The KO-TX mice (figure 33) had decreased
immunoreactivity especially in the glomerular layer than the other treatment groups.
Summary: Following lesion either apoE3 or apoE4 was adequate to produce some
recovery of synaptophysin.
Discussion

The results of this study revealed that apoE deficiency in apoE gene KO mice
leads to a delay in nerve recovery as compared to wild type mice. Expression of either
human apoE3 or human apoE4 can partially compensate for the absence of the wild type
gene. Nerve recovery appeared to follow the order: 1. wild type mice, 2. apoE3
transgenic equivalent to apoE4 transgenic, and 3. ApoE-KO mice.
In summary, the data suggest that apoE has a tremendous impact on neuronal

plasticity. Furthermore, human apoE3 was found to be equivalent to apoE4 in supporting
some degree of olfactory nerve repair in mice; however, neither was as good as the WT
apoE gene, and both were better than apoE-KO mice.
It is possible that the difference between apoE3 and apoE4 is just not
distinguishable at two weeks, but would be distinguishable at three or more weeks post-
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lesion. It is possible that apoE3 has a favorable affect on olfactory nerve recovery, but at
two weeks there are no differences. Therefore, the apoE3 gene mice might have
complete recovery in six weeks post lesion and apoE4 gene mice might take a week or
two longer for complete olfactory nerve recovery. ApoE4 may initially be able to handle
the recovery, but at some point beyond two weeks, its ability to keep up the regenerative
process may decrease.
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Conclusions
1. ApoE immuoreactivity surrounds the olfactory nerve and the glomeruli. This
suggests that apoE may be involved with degeneration and regeneration. The
olfactory bulb might be an ideal structure for determining the role of apoE in
degeneration and regeneration of nerves.
2. ApoE immuoreactivity increased in the olfactory nerve during degeneration
following lesion and increased in the olfactory bulb during the regeneration
process. ApoE is mostly produced by astrocytes, but also by microglia.
3. The absence of an apoE gene diminished the ability of the olfactory nerve to
recover following lesion.
4. Transgenic apoE3 or apoE4 partially compensate for the absence of a wild type
apoE gene, but neither was as good as the wild type gene.
5. These studies all suggest that apoE has a tremendous impact on olfactory nerve
recovery following lesion.
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Figure 1. Olfactoiy epithelium and olfactoiy bulb.

Figure 2. Lamina of the olfactoiy bulb. From outer to inner, olfactoiy nerve layer (onl), glomerular layer
(glom), external plexiform layer (epl), mitral cell layer (arrows on left), internal plexiform layer (ipl),
granule cell layer (gel) and ventricular layer (vent).
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Figure 3 A and B. ApoE immunoreactivity present in olfactory nerve and glomerular layer. Low power
view, arrowheads showing a lack ofimmunoreactivity in the mitral cell layer (ml) (A). High power view
(B).

Figure 4. ApoE immunoreactivity in the olfactory nerve (ON) and glomerular layer (G) in saline treated
(N).
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Figure 5. Intense apoE immunoreactivity in the olfacto:ry nerve three days post-lesion. Arrowhead
pointing to olfacto:ry nerve.

Figure 6. Increased apoE immunoreactivity in olfacto:ry nerve and glomerular layer seven days post-lesion.
Arrowhead pointing to olfacto:ry nerve.
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Figure 7. Increased apoE immunoreactivity in the glomerular layer at 14 days post-lesion.
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Figure 8. ApoE immunoreactivity was similar to non-lesioned mice at 21 days post-lesion.
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Figure 9. Double labeling of astroglia (A, C) and microglia (B, D) in the olfactoiy bulb at three days postlesion. Low power views of the gomerular layer show double labeling with DAB for apoE and BDHC
(blue granular) labeling for either GFAP (A) or F4/80 (B). The large arrowhead in A and B identify the
double-labeled perikarya shown in C and D. The smaller arrows represent apoE-producing cells not
labeled with the BDHC.

Figure 10. OMP immunoreactivity in WT-TX
mice at three days post-lesion. Intense immunoreactivity in olfactoiy nerve and moderate
reactivity in the glomeruli.

Figure 11. OMP immunoreactivity
KO-TX mice at three days postlesion. Intense immunoreactivty
In the olfactoiy nerve and moderate
reactivity in the glomeruli.

Figure 12. OMP immunoreactivity in WT-TX
mice at 21 days post-lesion. Intense
immunoreactivity in olfactoiy nerve and
moderate reactivity in the glomeruli.

Figure 13. OMP immunoreactivty
in KO-TX mice at 21 days postlesion. Intense reactivity in the
olfactoiy nerve with unorganized
glomeruli reactivity.
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Figure 14. Wild-type, GFAP immunoreactivity, saline treated. Intense reactivity
in the glomerular layer. All saline groups
were similar.

Figure 15. Wild-type, GFAP
immunoreactivity, two weeks
post-lesion. Intense immunoreactivity in the glomerular layer
and an overall increase in reactivity.

Figure 16. ApoE-KO, GFAP immunoreactivity, two weeks post-lesion. Intense
reactivity in glomerular layer and an overall
increase in reactivity.

Figure 17. ApoE4, GFAP
immunoreactivity two weeks
post-lesion. Intense reactivity in
the glomerular layer and an overall
increase in reactivity.

Figure 18. Wild-type, apoE immunoreactivity, saline treated. Diffuse reactivity
in the olfactory nerve and glomerular layer.

Figure 19. ApoE3, apoE immunoreactivity, saline treated. Astrogliallike staining in the glomerular layer.
ApoE4 was similar.
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Figure 20. Wild-type, apoE immunoreactivity, two weeks post-lesion.
Reactivity increased in olfactory nerve
and glomerular layer.

Figure 21. ApoE3, apoE immunoreactivity, two weeks post-lesion.
No increase in reactivity. ApoE4
was similar.

Figure 22. Wild-type, F4/80 immunoreactivity, saline treated. Moderate
reactivity in the glomerular layer and
external plexiform layer. All saline
groups were similar.

Figure 23. Wild-type, F4/80
immunoreactivity, two weeks postlesioin. Increased immunoreactivity
in the glomerular layer and external
plexiform layer.

Figure 24. ApoE-KO, F4/80 immunoreactivity, two weeks post-lesion.
Increased immunoreactivity in the
glomerular layer and external plexiform
layer.

Figure 25. ApoE3, F4/80 immunoreactivity, two weeks post lesion.
No increase in reactivity. ApoE4
was similar.
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Figure 26. Wild-type, OMP immunoreactivity, saline treated. Reactivity in
the olfactory nerve and glomerular layer.
All saline groups were similar.

Figure 27. Wild-type, OMP
immunoreactivity, two weeks postlesion. Gomeruli are smaller
compared to saline treated mice.

Figure 28. ApoE3, OMP immunoreactivity,
two weeks post-lesion. Less glomerular
reactivity than wild type mice. ApoE4
was similar.

Figure 29. ApoE-KO, OMP
immunoreactivity, two weeks postlesion. Less glomerular reactivity
than the transgenic mice.

Figure 30. Wild-type, Synaptophysin
immunoreactivity, saline treated. Intense
reactivity in the glomerular layer and
external plexiform layer. All saline
groups were similar.

Figure 31. Wild-type, Synaptophysin
immunoreactivity, two weeks postlesion. Attenuation of reactivity and
smaller glomeruli than saline treated
groups.
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Figure 32. ApoE4, Synaptophysin
immunoreactivity, two weeks post-lesion.
Smaller and lighter glomeruli than wildtype mice. ApoE3 was similar.

Figure 33. ApoE-KO, Synaptophysin immunoreactivity, two weeks
post-lesion. Decreased reactivity in
glomerular layer compared to the
wild type and transgenic lesioned
mice.
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